Bayer HealthCare, a subgroup of Bayer AG is one of the world’s leading, innovative companies in the healthcare and medical products industry, has launched the flea- and tick-collar Seresto for cats and dogs in the US-market. The innovative collar consists of a patented polymermatrix which releases a combination of the proven active ingredients imidacloprid and flumethrin in controlled, very low doses, maintaining the necessary level of active ingredient.

This gives a continuous eight months protection against fleas and ticks in cats and dogs. With Seresto Bayer provides for the first time ever a cat-product to repel ticks, which means that ticks cannot attach to the cat, and therefore minimize the risk of tick transmitted diseases.

“With Seresto, we are now happy to offer an effective long-term protection for cats and dogs also in the US,” said Dr Dirk Ehle, Head of Bayer HealthCare’s Animal Health division. “This nicely complements our parasiticide product portfolio with monthly application. Pet owners now have the choice which treatment is best and most convenient for them and their pet against fleas and ticks.”

According to market studies, pet owners tend to forget to re-apply the monthly treatment on schedule which results in a lack of protection until the product is used again. This gap does not occur when using the long-term collar due to its special release mechanism.

Seresto represents a major advance in the development of ectoparasiticides. The unique polymer matrix of Seresto provides dose adjusted release of two proven active ingredients: imidacloprid, a very potent insecticide, and flumethrin, a highly effective acaricide. Research into the efficacy of this combination has demonstrated that these two active ingredients work synergistically to significantly increase their efficacy against fleas. Laboratory trials confirm that the combination of imidacloprid and flumethrin is 100 times more effective against fleas than imidacloprid alone. Thanks to its innovative polymer matrix composition, the migration of active ingredients from the Seresto collar matrix to the surface adjusts depending on the concentrations of active ingredients within the lipid layer on the pet´s skin. This ensures a steady, low-dose release profile, providing optimal protection for up to eight months. In Europe and New Zealand Seresto is already available on the market since 2012.

The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials.